19th Aug 2008 17:21
19 August 2008
NOTICE OF 2008 HALF YEAR RESULTS
Vernalis plc (LSE :VER) today announces that it will be releasing its interim results for the six months ended 30 June 2008 on Thursday, 28 August 2008.
- ends -
Enquiries:
|
Vernalis plc |
+44 (0) 118 977 3133 |
|
Peter Fellner, Executive Chairman |
|
|
Tony Weir, Chief Financial Officer |
|
|
|
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles |
|
|
Justine McIlroy |
|
Notes to Editors
About Vernalis
Vernalis is a pharmaceutical company with one marketed product, Frova®, and six products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Endo, Menarini and Chiesi:
|
Product
|
Indication
|
Phase I
|
Phase II
|
Phase III
|
Registration
|
Market
|
Marketing Rights
|
|
Frova®
|
Migraine
|
|
|
|
|
X
|
Endo/Menarini (Royalties)
|
|
Frova®
|
Menstrual Migraine
|
|
|
X
|
|
|
Endo/Menarini (Royalties)
|
|
V1512
|
Parkinson’s Disease
|
|
X
|
|
|
|
World Wide (excl. Italy)
|
|
V10153
|
Ischaemic Stroke
|
|
X
|
|
|
|
Worldwide
|
|
V3381
|
Neuropathic Pain
|
|
X
|
|
|
|
Worldwide
|
|
V2006
|
Parkinson’s Disease
|
|
X
|
|
|
|
Biogen Idec (Milestone & Royalties)
|
|
V24343
|
Obesity/
Diabetes
|
X
|
|
|
|
|
Worldwide
|
|
AUY922
|
Cancer
|
X
|
|
|
|
|
Novartis (Milestone & Royalties)
|
|
Hsp90-Oral
|
Cancer
|
|
|
|
|
|
Novartis (Milestone & Royalties)
|
|
|
Cancer
|
|
|
|
|
|
Servier (Milestone & Royalties)
|
For further information about Vernalis, please visit www.vernalis.com.
Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Related Shares:
Vernalis PLC